Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 1, 2014, Pages 67-73

  Ikehata, Mika ^a   Ogawa, Mao ^a   Yamada, Yasuki ^a   Tanaka, Shota ^a   Ueda, Kumiko ^a   Iwakawa, Seigo ^a  

^a KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Colorectal cancer; DNA methyltransferase inhibitor; Histone deacetylase inhibitor; Isobologram; Synergism

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA METHYLTRANSFERASE INHIBITOR; FIRTECAN; FLUOROURACIL; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; OXALIPLATIN; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; COLORECTAL CANCER; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG POTENTIATION; EPIGENETICS; HUMAN; HUMAN CELL; IC 50; PHARMACOGENETICS;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CAMPTOTHECIN; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA; DNA MODIFICATION METHYLASES; DRUG SYNERGISM; EPIGENESIS, GENETIC; FLUOROURACIL; HCT116 CELLS; HISTONE DEACETYLASE INHIBITORS; HT29 CELLS; HUMANS; ORGANOPLATINUM COMPOUNDS;

EID: 84892618312     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00574     Document Type: Article

References (28)

1. Crea F, Nobili S, Paolicchi E, Perrone G, Napoli C, Landini I, Danesi R, Mini E. Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist. Updat., 14, 280-296 (2011).
2. Köhne CH, Lenz HJ. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist, 14, 478-488 (2009).
3. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat. Biotechnol., 28, 1069-1078 (2010).
4. Steensma DP. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes? Best Pract. Res. Clin. Haematol., 25, 443-451 (2012).
5. Mahfouz RZ, Jankowska A, Ebrahem Q, Gu X, Visconte V, Tabarroki A, Terse P, Covey J, Chan K, Ling Y, Engelke KJ, Sekeres MA, Tiu R, Maciejewski J, Radivoyevitch T, Saunthararajah Y. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin. Cancer Res., 19, 938-948 (2013).
6. Ganetsky A. The role of decitabine for the treatment of acute myeloid leukemia. Ann. Pharmacother., 46, 1511-1517 (2012).
7. Giannini G, Cabri W, Fattorusso C, Rodriquez M. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Med. Chem., 4, 1439-1460 (2012).
8. Cherblanc F, Chapman-Rothe N, Brown R, Fuchter MJ. Current limitations and future opportunities for epigenetic therapies. Future Med. Chem., 4, 425-446 (2012).
9. Ishiguro M, Iida S, Uetake H, Morita S, Makino H, Kato K, Takagi Y, Enomoto M, Sugihara K. Effect of combined therapy with lowdose 5-aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15. Ann. Surg. Oncol., 14, 1752-1762 (2007).
10. Noguchi T, Tanimoto K, Shimokuni T, Ukon K, Tsujimoto H, Fukushima M, Noguchi T, Kawahara K, Hiyama K, Nishiyama M. Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin. Cancer Res., 10, 7100-7107 (2004).
11. Flis S, Gnyszka A, Misiewicz-Krzemińska I, Spławiń ski J. Decytabine enhances cytotoxicity induced by oxaliplatin and 5-fluorouracil in the colorectal cancer cell line Colo-205. Cancer Cell Int., 9, 10-19 (2009).
12. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res., 63, 7291-7300 (2003).
13. Fazzone W, Wilson PM, Labonte MJ, Lenz HJ, Ladner RD. Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. Int. J. Cancer, 125, 463-473 (2009).
14. Na YS, Jung KA, Kim SM, Hong YS, Ryu MH, Jang SJ, Moon DH, Cho DH, Kim JC, Lee JS, Kim TW. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models. Cancer Chemother. Pharmacol., 68, 389-398 (2011).
15. Na YS, Kim SM, Jung KA, Yang SJ, Hong YS, Ryu MH, Ro S, Cho DH, Kim JC, Jin DH, Lee JS, Kim TW. Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts. Oncol. Rep., 24, 1509-1514 (2010).
16. de la Chapelle A. Microsatellite instability. N. Engl. J. Med., 349, 209-210 (2003).
17. Sinicrope FA, Sargent DJ. Molecular pathways: Microsatellite instability in colorectal cancer: Prognostic, predictive, and therapeutic implications. Clin. Cancer Res., 18, 1506-1512 (2012).
18. Lind GE, Danielsen SA, Ahlquist T, Merok MA, Andresen K, Skotheim RI, Hektoen M, Rognum TO, Meling GI, Hoff G, Bretthauer M, Thiis-Evensen E, Nesbakken A, Lothe RA. Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol. Cancer, 10, 85-99 (2011).
19. Ikehata M, Ueda K, Iwakawa S. Different involvement of DNA methylation and histone deacetylation in the expression of solutecarrier transporters in 4 colon cancer cell lines. Biol. Pharm. Bull., 35, 301-307 (2012).
20. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy- chemotherapy: The concept of additivity. Int. J. Radiat. Oncol. Biol. Phys., 5, 85-91 (1979).
21. Kano Y, Akutsu M, Tsunoda S, Izumi T, Mori K, Fujii H, Yazawa Y, Mano H, Furukawa Y. Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro. Cancer Chemother. Pharmacol., 54, 505-513 (2004).
22. Shingu T, Yamada K, Hara N, Moritake K, Osago H, Terashima M, Uemura T, Yamasaki T, Tsuchiya M. Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells. Cancer Res., 63, 4044-4047 (2003).
23. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev., 58, 621-681 (2006).
24. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen RW, Ahuja N, Brock MV, Stearns V, Feller-Kopman D, Yarmus LB, Lin YC, Welm AL, Issa JP, Minn I, Matsui W, Jang YY, Sharkis SJ, Baylin SB, Zahnow CA. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell, 21, 430-446 (2012).
25. Nguyen AN, Hollenbach PW, Richard N, Luna-Moran A, Brady H, Heise C, MacBech K. Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines. Lung Cancer: Targets and Therapy, 1, 119-140 (2010).
26. Morita S, Iida S, Kato K, Takagi Y, Uetake H, Sugihara K. The synergistic effect of 5-aza-2′-deoxycytidine and 5-fluorouracil on drug-resistant tumors. Oncology, 71, 437-445 (2006).
27. Flis S, Gnyszka A, Flis K, Spławiński J. MS275 enhances cytotoxicityinduced by 5-fluorouracil in the colorectal cancer cells. Eur. J. Pharmacol., 627, 26-32 (2010).
28. Flis S, Gnyszka A, Spławiński J. HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines. Biochem. Biophys. Res. Commun., 387, 336-341 (2009).